Devices

FDA Plans to Exempt Low-Risk Devices From 510(k) Requirements

FDA has issued a guidance document outlining its intent to exempt several low-risk, unclassified medical devices from premarket notification requirements, a move aimed at reducing regulatory burdens on manufacturers while maintaining existing safety and quality controls.

Under the guidance, FDA said it does not intend to enforce compliance with 510(k) premarket notification requirements for a group of unclassified devices that the agency believes meet the statutory standards for exemption. The guidance covers a range of preamendment unclassified devices across multiple medical specialties, including hearing protection products, speech-training aids for hearing-impaired patients, hemorrhoid cushions, nail prostheses, fertility diagnostic devices, spinal curvature monitors, acupressure devices, isoniazid test strips and ophthalmic eye cups.

As a result, manufacturers of the affected products are not expected to submit new 510(k) applications while FDA moves toward formal exemption of the devices. The agency said the policy reflects its ongoing efforts to streamline oversight of products that pose relatively low risks to patients and users.

The agency emphasized that the proposed exemptions would apply only to premarket notification requirements and would not relieve manufacturers of other regulatory obligations. Companies would still be required to comply with registration and listing requirements, labeling rules, quality management system regulations, and medical device reporting requirements.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome